Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 9/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CDC25A | P30304 | 4/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | VDR | P11473 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16163587 | 1.00 | NPC1L1 (0.57) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL20678563 | 0.99 | NPC1L1 (0.56) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL20678564 | 0.99 | NPC1L1 (0.56) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL16163498 | 0.99 | NPC1L1 (0.56) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL14976110 | 0.99 | NPC1L1 (0.56) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL16163916 | 0.98 | NPC1L1 (0.56) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL14977053 | 0.98 | NPC1L1 (0.56) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL16163915 | 0.97 | NPC1L1 (0.59) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL14976569 | 0.97 | NPC1L1 (0.59) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL14975989 | 0.96 | NPC1L1 (0.59) | NPC1L1USP2MEN1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2782923-B1 | PROCESS FOR THE PREPARATION OF STEROL DERIVATIVES | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-11-23 | — | — | EP | claimed |
| US-9447141-B2 | Process for the preparation of sterol derivatives | (INSERM) (Institut National de la Sante et de la Recherche Medicale) (FR) | 2016-09-20 | — | — | US | claimed |
| US-20140309417-A1 | PROCESS FOR THE PREPARATION OF STEROL DERIVATIVES | DENDROGENIX SA (BE) | 2014-10-16 | — | — | US | claimed |
| EP-2782923-A1 | PROCESS FOR THE PREPARATION OF STEROL DERIVATIVES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-10-01 | — | — | EP | claimed |
| WO-2013076257-A1 | PROCESS FOR THE PREPARATION OF STEROL DERIVATIVES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2013-05-30 | — | — | WO | claimed |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-20190125745-A1 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. | 2019-05-02 | — | — | US | disclosed |
| WO-2018222975-A1 | METHODS FOR THE TREATMENT OF CANCER | RGENIX, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| EP-3402477-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | The Rockefeller University (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017123568-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| US-9447141-B2 | Process for the preparation of sterol derivatives | (INSERM) (Institut National de la Sante et de la Recherche Medicale) (FR) | 2016-09-20 | — | — | US | disclosed |
| US-20140309417-A1 | PROCESS FOR THE PREPARATION OF STEROL DERIVATIVES | DENDROGENIX SA (BE) | 2014-10-16 | — | — | US | disclosed |
| EP-2782923-A1 | PROCESS FOR THE PREPARATION OF STEROL DERIVATIVES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013076257-A1 | PROCESS FOR THE PREPARATION OF STEROL DERIVATIVES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309417-A1 | PROCESS FOR THE PREPARATION OF STEROL DERIVATIVES | NR1H3, DHCR7, LSS | NPC1L1 49/4885USP2 3557/4885MEN1 2046/4885 |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | NPC1L1 637/4885USP2 2518/4885MEN1 3539/4885 |
| US-20190125745-A1 | TREATMENT AND DIAGNOSIS OF CANCER | NR1H4, NR1H3, NR1H2 | NPC1L1 1478/4885USP2 2895/4885MEN1 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.